Search company, investor...

NeurAxon

nrxn.com

Founded Year

2004

Stage

Corporate Minority | Alive

Total Raised

$28.84M

Last Raised

$1.75M | 8 yrs ago

About NeurAxon

NeurAxon is discovering and developing next generation pain therapeutics focused on the inhibition of neuronal nitric oxide synthase (nNOS), an enzyme involved in modulating pain and central nervous system neuronal sensitization. NeurAxon's lead product candidate, NXN-188, is a first-in-class, dual-action small molecule incorporating both nNOS inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.

Headquarters Location

2395 Speakman Drive Suite 1001

Mississauga, Ontario, L5K 1B3,

Canada

Missing: NeurAxon's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NeurAxon's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing NeurAxon

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeurAxon is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

NeurAxon Patents

NeurAxon has filed 1 patent.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/17/2008

3/18/2014

Prodrugs, Sensory systems, Rare diseases, Urinary system, Abdomen

Grant

Application Date

11/17/2008

Grant Date

3/18/2014

Title

Related Topics

Prodrugs, Sensory systems, Rare diseases, Urinary system, Abdomen

Status

Grant

Latest NeurAxon News

Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor Drug Pipeline Market Report 2022 Featuring NeurAxon & Arbor Vita - ResearchAndMarkets.com

Feb 9, 2022

"Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor - Pipeline Insight, 2022" report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type. Descriptive coverage of pipeline development activities for Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details. Pipeline Therapeutics assessment of products for Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor The report assesses the active Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor pipeline products by developmental stage, product type, molecule type, and administration route. Scope of the Report Provides a snapshot of the therapeutics pipeline activity for Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor Features the Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Neuronal Nitric Oxide Synthase (nNOS or Type I NOS) Inhibitor Key Topics Covered:

NeurAxon Frequently Asked Questions (FAQ)

  • When was NeurAxon founded?

    NeurAxon was founded in 2004.

  • Where is NeurAxon's headquarters?

    NeurAxon's headquarters is located at 2395 Speakman Drive, Mississauga.

  • What is NeurAxon's latest funding round?

    NeurAxon's latest funding round is Corporate Minority.

  • How much did NeurAxon raise?

    NeurAxon raised a total of $28.84M.

  • Who are the investors of NeurAxon?

    Investors of NeurAxon include Knight Therapeutics, H.I.G. BioHealth Partners, Delphi Ventures, Ventures West, OrbiMed Advisors and 9 more.

  • Who are NeurAxon's competitors?

    Competitors of NeurAxon include Tetraphase Pharmaceuticals, CoLucid Pharmaceuticals, Afferent Pharmaceuticals, Alexza Pharmaceuticals, NeurOP and 11 more.

Compare NeurAxon to Competitors

N
Neurotide

Neurotide is developing pain killers based on the body's own natural pain killer, endomorphin. Synthesised endomorphin can relieve pain when delivered directly to the brain, but has a short life span and is unsuitable as a drug without modifications. Neurotide is developing an orally available form of endomorphin for the treatment of chronic and acute pain as well as a new treatment for neuropathic pain, which can be caused by diabetes, injury and certain infections.

P
Paeptor Pharma

Painceptor develops peripherallyactive pharmaceuticals for the treatment and management of pain. Per the company, Painceptors researchers and industrial collaborators have advanced a series of highly selective organic molecules which will alleviate pain in a number of debilitating untreated diseases. PainCeptors therapeutics relieve pain by intercepting tissue specific pain at the source and promoting a receptive physiological environment for relief of chronic and acute pain.

N
NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

E
Emagin Therapeutics

Emagin Therapeutics develops new and improved drug entities to treat acute, chronic and cancer-related pain and delivery systems for pain management.

S
Symphony Allegro

Symphony Allegor is a drug company focused on treatment of acute agitation in patients with schizophrenia and bipolar disorder

C
Cervelo Pharmaceuticals

Cervelo Pharmaceuticals is a semi-virtual clinical development company founded in 2006. The Company is focused on the in-licensing and development of mid stage neurology small molecule drug candidates. It currently has exclusive worldwide rights for all indications to a small molecule, first in class, drug candidate, which has demonstrated a safe and potentially effective capability against neuropathic and inflammatory pain, as well as inflammation.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.